• strep
  • Patients with advanced, unresectable NETs of pancreatic, gastrointestinal foregut or unknown primary site were randomised to receive three-weekly capecitabine (Cap) 625 mg/m(2) twice daily orally, streptozocin (Strep) 1.0 g/m(2) intravenously on day 1, with or without cisplatin (Cis) 70 mg/m(2) intravenously on day 1. (nih.gov)
  • health
  • If you notice pain, redness or swelling at the IV site while you are receiving streptozocin, alert your health care professional immediately. (chemocare.com)
  • The amount of streptozocin that you will receive depends on many factors, including your height and weight, your general health or other health problems, and the type of cancer or condition being treated. (chemocare.com)
  • people
  • Streptozocin is reserved for use in people who are having symptoms or who have cancer that has spread to other areas of the body (metastasized) and is continuing to progress. (emedtv.com)
  • Days
  • Patients with progressive metastatic, well-differentiated P-NET received a minimum of 6 month treatment of bevacizumab at 7.5 mg/kg IV on d1 q3w with 5-FU at 400 mg/m2/day and streptozocin at 500 mg/m2/day IV from d1 to d5 every 42 days. (nih.gov)